{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-126061","form_type":"8-K","ticker":"PRPO","cik":"0001043961","company_name":"Precipio, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.010560+00:00","generated_at":"2026-06-07T12:30:32.252735+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Precipio achieves two of three 2023 goals; revenue up ~50% YoY, cash burn cut 60%","bullets":["Pathology division hit $14M annualized revenue in Q3, meeting target #1; product target lowered to $6M.","Quarterly cash burn reduced from $2.5M (Q3-2022) to $1M (Q3-2023), exceeding target #3.","Q3 2023 total revenue $4.5M (50% YoY gain); annualized run-rate ~$18.5M.","Expects Q4 2023 revenue $3.2-$3.5M, FY 2023 total ~$14.5M vs $9.8M in 2022.","If ~50% growth continues, positive cash flow possible in H2 2024 at ~$30M annual run-rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-126061","json":"https://secwatch.observer/filing/0001104659-23-126061.json","markdown":"https://secwatch.observer/filing/0001104659-23-126061.md","text":"https://secwatch.observer/filing/0001104659-23-126061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043961/000110465923126061/0001104659-23-126061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043961/000110465923126061/tm2332910d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:30:32.252735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}